Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies

Ivosidenib is a once daily (q.d.), orally available, potent mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor approved for treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and intensive chemotherapy ineligible AML with a susceptible IDH1 mutation. Population pha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Sci
Main Authors: Jiang, Xuemin, Wada, Russ, Poland, Bill, Kleijn, Huub Jan, Fan, Bin, Liu, Guowen, Liu, Hua, Kapsalis, Stephanie, Yang, Hua, Le, Kha
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8212730/
https://ncbi.nlm.nih.gov/pubmed/33493392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12959
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados